Rasburicase

DB00049ApprovedInvestigationalProtein Based TherapiesUric Acid-specific Enzyme

Rasburicase is a recombinant form of urate-oxidase enzyme used to treat hyperuricemia following chemotherapy for leukemias and non-Hodgkin's lymphoma. Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain.

Protein structure of Rasburicase
Mechanism
Curator reviewed
Primary indication
For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)Curator reviewed · 3 structured indications
Formula / weight
C1521H2381N417O461S7 · 34109.5 Da
First approval
Canada, 2006 · United States, 2002 · European Union, 2016
Also known as
Recombinant urate oxidase · Urate oxidase
Code names
SR-29142
Brand names
  • Elitek
  • Fasturtec

Resolves to

Compound
UNII08GY9K1EUOCAS134774-45-1ChEMBLCHEMBL1201594
Clinical / RWD
RxNorm283821ATCM04AX01ATCV03AF07PharmGKBPA10176

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
53Drug interactionsStructured to mechanism, not free text
Sign in
32Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
4ContraindicationsEach with its own population and attribute set
Sign in
13Marketed productsAcross 7 countries and 5 labellers
Sign in
2ATC codesIncluding every combination product, plus 10 drug categories
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Rasburicase, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In